SCHEMBL3476937

SCHEMBL3476937

Cc1ccccc1S(=O)(=O)Nc1cscn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 11/20 0.50
SCN8A Q9UQD0 11/20 0.50
SCN5A Q14524 10/20 0.50
PKM P14618 1/20 0.48
ALDH1A1 P00352 2/20 0.48
TP53 P04637 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
SCN1B Q07699 3/20 0.47
SLC40A1 Q9NP59 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
EDNRA P25101 1/20 0.47
NR1I2 O75469 1/20 0.46
CYP2C9 P11712 1/20 0.46
SCN9A Q15858 1/20 0.46
SCN2A Q99250 1/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
KDM1A O60341 1/20 0.45
MAOA P21397 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31017719 0.84 MAPT (0.46) SCN1ASCN8ASCN5ASCN1BNR1I2
SCHEMBL1093291 0.82 SCN1A (0.55) SCN1ASCN8ASCN5ASCN1BNR1I2
SCHEMBL1094122 0.78 SCN9A (0.52) SCN1ASCN8ASCN5ASCN1BSLC40A1
Formic Acid SCHEMBL31018026 0.78 MAPT (0.41) SCN1ASCN8ASCN5ASCN1B
SCHEMBL1093964 0.78 SCN1A (0.54) SCN1ASCN8ASCN5APKMALDH1A1
SCHEMBL1094411 0.77 SCN8A (0.59) SCN1ASCN8ASCN5ASCN1BNR1I2
SCHEMBL29669204 0.77 SCN8A (0.59) SCN1ASCN8ASCN5ASCN1BNR1I2
SCHEMBL15258968 0.76 SCN9A (0.56) SCN1ASCN8ASCN5ASCN1BSCN9A
Formic Acid SCHEMBL29669154 0.76 SCN1A (0.50) SCN1ASCN8ASCN5ASCN1BNR1I2
SCHEMBL8797021 0.76 SCN1A (0.44) SCN1ASCN8ASCN5ASCN1BEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 US disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 US disclosed
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 SCN1A 23/4885SCN8A 32/4885SCN5A 19/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 SCN1A 23/4885SCN8A 32/4885SCN5A 19/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B SCN1A 1/4885SCN8A 14/4885SCN5A 11/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B SCN1A 1/4885SCN8A 14/4885SCN5A 11/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 SCN1A 23/4885SCN8A 32/4885SCN5A 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.